Antithrombin III human
- Generic Name
- Antithrombin III human
- Brand Names
- Thrombate III
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9000-94-6
- Unique Ingredient Identifier
- T0LTO7L82X
- Background
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
- Indication
Antithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
- Associated Conditions
- Hereditary antithrombin III deficiency
- Associated Therapies
- -
Antithrombin III and Post-liver Transplantation Acute Kidney Injury
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 2395
- Registration Number
- NCT04912193
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Antithrombin III in Infectious Disease Caused by COVID-19
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Enrique Ginzburg
- Target Recruit Count
- 52
- Registration Number
- NCT04899232
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 300
- Registration Number
- NCT04651400
- Locations
- 🇸🇪
ECMO Centre Karolinska, Stockholm, Sweden
🇩🇪Octapharma Research Site, Essen, Germany
Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Jonathan Stine
- Registration Number
- NCT04055389
- Locations
- 🇺🇸
Penn State College of Medicine, Hershey, Pennsylvania, United States
Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 27
- Registration Number
- NCT02631174
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 6
- Registration Number
- NCT01698567
- Locations
- 🇺🇸
Michael Eaton, MD, Rochester, New York, United States
Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 18
- Registration Number
- NCT01530737
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- University of Bari
- Target Recruit Count
- 90
- Registration Number
- NCT01201070
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico, Bari, Italy
Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
- Conditions
- Interventions
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Instituto Grifols, S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT00823082
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, Milano, Lombardy, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.